Sou Hu Cai Jing·2025-10-24 16:42Core Viewpoint - Minsheng Securities has faced regulatory penalties twice this year due to violations in its investment banking business, leading to a decline in revenue and gross margin in the first half of the year [2][10]. Regulatory Actions - On October 21, Minsheng Securities and two sponsoring representatives received a warning letter from the Zhejiang Regulatory Bureau related to their sponsorship of Weikang Pharmaceutical's IPO, highlighting failures in continuous supervision and information disclosure [2][4]. - In July, Weikang Pharmaceutical was fined 5 million yuan for failing to disclose related party non-operating fund occupation and inaccuracies in its convertible bond prospectus, with total penalties for responsible individuals amounting to 9.6 million yuan [2][4]. Business Performance - In the first half of 2025, Minsheng Securities reported operating revenue of 1.88 billion yuan, a year-on-year increase of 15.02%, while net profit attributable to shareholders was 562 million yuan, up 67.95% [10]. - However, the investment banking segment's revenue decreased by 36.36% to 343 million yuan, with gross margin dropping from 27.14% to 8.14%, attributed to reduced business scale due to market conditions [10]. Corporate Changes - In February, Guolian Securities acquired Minsheng Securities, rebranding it as Guolian Minsheng, and is currently integrating the investment banking operations [3][8]. - Following the acquisition, Minsheng Securities' existing projects and operations are being transferred to Guolian Minsheng's underwriting and sponsorship subsidiary [8][9]. Compliance Issues - The warning letter from the Zhejiang Regulatory Bureau indicated that Minsheng Securities failed to adequately monitor Weikang Pharmaceutical's construction project delays and had deficiencies in internal controls during the continuous supervision process [4][6]. - Minsheng Securities' reports often concluded with "no issues found," despite ongoing compliance problems at Weikang Pharmaceutical, which has faced multiple regulatory penalties since its IPO in 2020 [5][7].